Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts.

Abstract

Age-related macular degeneration (AMD) is the leading cause of blindness in elderly patients. The more aggressive exudative form is characterized by abnormal blood-vessel development that occurs beneath the retina as a result of choroidal neovascularization (CNV). Vascular endothelial growth factor (VEGF) has emerged as the key mediator of CNV formation; this has led to intensive research on VEGF and the recent approval of anti-VEGF compounds by the US Food and Drug Administration. Despite this successful introduction of anti-angiogenic therapies into the clinical setting, there is still a lack of treatments that definitively reverse damaged vision. Here, we consider the importance of putative molecular targets other than VEGF that might have been underestimated. Emerging cellular mechanisms offer additional opportunities for innovative therapeutic approaches.

3 Figures and Tables

02040200920102011201220132014201520162017
Citations per Year

142 Citations

Semantic Scholar estimates that this publication has 142 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Nol2007AntiangiogenicTO, title={Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts.}, author={Agn{\'e}s No{\"{e}l and Maud Jost and Vincent Lambert and Julie Lecomte and J M Rakic}, journal={Trends in molecular medicine}, year={2007}, volume={13 8}, pages={345-52} }